ABSTRACT A murine hybridoma has been obtained that produces a monoclonal antibody against the human transferrin receptor. In contrast to previously characterized monoclonal antibodies that recognize the transferrin receptor, this antibody, designated 42/6, blocks the binding of transferrin to its receptor and inhibits the growth of the human T leukemic cell line, CCRF-CEM, in vitro. Inhibition of cell growth was dose dependent, and as little as 2.5 jtg of purified antibody per ml had a detectable effect, even though transferrin was present in the tissue culture medium in large molar excess. Cells grown in the presence of antibody for 7 days accumulated in S phase of the cell cycle. The addition of iron to antibody-treated cultures in the form of ferric complexes or ferrous sulfate did not overcome the growth inhibitory effects of the anti-transferrin-receptor antibodies. This result suggests that either transferrin is the only means by which CCRF-CEM leukemic cells can be provided with sufficient iron in vitro or that other factors in addition to iron starvation are involved in the antibody-mediated growth inhibition. The inhibition of cell growth by 42/6 monoclonal antibody suggests that monoclonal antibodies against proliferation-associated cell surface antigens, such as the transferrin receptor, may be useful pharmacological reagents to modify-cell growth in vitro.
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Iron plays an important role in cell growth and metabolism (1) . Key reactions in energy metabolism and DNA synthesis are catalyzed by iron-containing enzymes, and it has been known for several years that transferrin, the major serum iron-transport protein, is an obligatory growth factor for cells growing in vitro (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . More recently, it has become apparent that cell surface receptors for transferrin are not only found in abundance on maturing erythroid cells and placental membranes but are expressed on proliferating cells in vitro and in vivo (12) (13) (14) (15) (16) .
We and others have obtained monoclonal antibodies that react with the human cell surface receptor for transferrin and confirmed that the expression of transferrin receptors is regulated by the growth state ofthe cells (17) (18) (19) (20) (21) (22) . Although the antitransferrin-receptor monoclonal antibody, which we obtained and designated B3/25, inhibits the growth of a human melanoma cell line in nude mice (23), it does not interfere with either transferrin binding or cell growth in vitro. In this paper, we report the identification ofanother murine monoclonal antibody against-the human transferrin receptor that blocks transferrin binding and show that this antibody blocks the growth of a human T leukemic cell line in vitro.
MATERIALS AND METHODS Cell Lines. CCRF-CEM, a human thymus-derived (T) leukemic cell line (24) , was grown in RPMI 1640 medium supplemented with 10% horse serumn. BW5147, a murine T lymphoma cell line (25) was grown in Dulbecco's modified Eagle's medium supplemented with 10% horse serum.
Monoclonal Antibodies. Monoclonal antibodies B3/25 and T56/14 directed against the human transferrin receptor and monoclonal antibody T29/33 specific for human T200 glycoprotein have been described (17, 18, 26) . Monoclonal antibody 42/6, the principal subject of this report, was obtained by immunizing BALB/c mice with purified human transferrin-receptor glycoprotein isolated from CCRF-CEM cells by affinity chromatography on a B3/25 monoclonal antibody column (18) .
An initial subcutaneous injection of 50 jig of glycoprotein in complete Freund's adjuvant was given, followed by an intravenous injection of 50 ug of glycoprotein in saline 6 wk later. The mice were sacrificed 4 days later, and the immune spleen cells were hybridized with S194/5.XXO.BU.1 myeloma cells by standard procedures (27, 28 (29) . Cell growth was assessed by counting with a Coulter Counter, and the distribution of cells throughout the cell cycle was measured by flow cytometric analysis offixed cells stained with mithramycin (30) . Ferric-fructose complexes were prepared by mixing fructose with FeCl3 in a molar ratio of 200:1 at pH 3.0, and ferric-nitrilotriacetic acid complexes were prepared by mixing the complexing agent with FeCl3 in a molar ratio of 2:1 at pH 3.0 (6). Both were added to cultures to give a final concentration of20 ,uM iron(III). Ferrous sulfate was dissolved in water at pH 3.0 and added (10 pmoV ml) daily to cultures.
Immunological and Biochemical Procedures. Trace 125I-labeled antibody binding assays, cell surface iodination, immu-
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RESULTS

Characterization of a Monoclonal Antibody Against the Human Transferrin Receptor that Blocks Transferrin Binding.
To obtain a monoclonal antibody that blocks the binding of transferrin to its receptor on the surface ofhuman cells, we employed the following strategy. Mice were immunized with purified human transferrin-receptor glycoprotein, and hybridomas were prepared between the spleen cells of the immune mice-and S194/5.XXO.BU.1 myeloma cells. Culture supernatants of these hybridomas were then tested sequentially for the presence of antibodies that (i) bound to CCRF-CEM cells, (ii) immunoprecipitated labeled transferrin receptor from lysates of surface-iodinated CCRF-CEM cells, and, when preincubated with CCRF-CEM cells, (iii) inhibited the binding of "2I-labeled human transferrin. This approach led to the identification of a monoclonal antibody designated 42/6 that gave positive results in each of these tests.
Inhibition of transferrin binding by preincubation ofthe cells with 42/6 tissue culture supernatant was dose-dependent ( Fig.  1) . At a dilution of 1:64, the hybridoma supernatant inhibited "WI-labeled binding to the same extent as did 15 tkg ofunlabeled human transferrin per ml. In contrast, undiluted culture supernatants containing antibodies B3/25 and T56/14 to human transferrin receptor or antibody T29/33 to human T200 glycoprotein had no effect on transferrin binding (data not shown). Immunoprecipitation studies showed that 42/6 monoclonal antibody did not react with human transferrin, ruling out the possibility that inhibition of binding was the result of a direct interaction with transferrin. 42/6 monoclonal antibody was typed as IgA (k) by immunoprecipitation ofantibody metabolically labeled with [3S]methionine with isotype-specific antisera (Miles). The hybridoma producing 42/6 monoclonal antibody has been repeatedly cloned by limit dilution and is moderately stable for antibody production. (Fig. 2) . Instead of the usual heterogeneity in cell size evident in exponentially growing cultures of CCRF-CEM cells, the antibody-treated cells appeared uniformly large. Cell growth was inhibited in a dose-dependent fashion by the antibody, and little or no increase in cell number was observed in cultures treated with the highest amount of antibody (Fig. 3) . Control experiments showed that the monoclonal antibody did not inhibit the growth of the murine BW5147 T lymphoma cell line consistent with its lack ofreactivity with the murine transferrin receptor. After 7 days of growth, cells from the same experiment shown in Fig. 3 were harvested, and their DNA content was analyzed by mithramycin staining. A striking difference was found in the cell cycle distribution of the antibody-treated cells and the control cells (Fig. 4) -63% of the cells were in S phase of the cell cycle as judged by mithramycin staining.
Growth Inhibition by the Transferrin-Blocking Anti-Transferrin-Receptor Antibody is Not Overcome by Fe'. The most likely explanation to account for the growth inhibitory effect of 42/6 monoclonal antibody was that by interfering with the binding of transferrin to its cell surface receptor, the antibodytreated cells were being deprived of iron. Indeed, the uptake ofiron from human [5"Fe] transferrin is completely inhibited by the antibody (unpublished results). If so, then we thought it should be possible to overcome the inhibitory effects of the antibody by providing the cells with iron in the form of soluble ferric-fructose complexes or by daily addition offerrous sulfate. For these experiments we used purified 42/6 monoclonal antibody. As little as 2.5 Ag of monoclonal antibody per ml produced significant inhibition of cell growth (Fig. 5) . However, the effects of the antibody could not be overcome by daily addition of 10 pmol of ferrous sulfate per ml. In similar experiments 20 A.M ferric-fructose and 20 1LM ferric-nitrilotriacetic acid complexes were also ineffective in preventing antibodymediated growth inhibition, although in a few experiments in the presence of ferric complexes, the proportion of cells found in S phase in antibody-treated cultures was reduced, and a small increase in cell number was observed relative to cultures to which antibody but not ferric complexes were added.
DISCUSSION
We describe here a murine monoclonal antibody against the human transferrin receptor that interferes with transferrin binding to cells and inhibits cell growth in vitro. These properties distinguish this antibody from other monoclonal antibodies to human transferrin receptor described earlier (17) (18) (19) (20) (21) (22) provide new possibilities for studying the growth requirements ofboth normal and malignant cells in vitro. The detailed mechanism of action of the antibody remains to be established.
A reasonable interpretation of the data is that the antibody binds to a site close to but not identical with the transferrin binding site on the transferrin receptor and, thus, inhibits binding oftransferrin. Preliminary data suggests that the 42/6 monoclonal antibody has a higher affinity for the transferrin receptor than transferrin itself and inhibits transferrin binding in a competitive manner (unpublished results). This would explain how growth inhibition by the monoclonal antibody is observed, even in the presence of the substantial molar excess of transferrin derived from the serum supplement to the tissue culture medium.
However, other more complex mechanisms involving interference with recycling of the receptors by 42/6 antibody or some other mechanism involving loss of the receptors from the cell surface cannot be ruled out. Crossblocking experiments with 42/6 monoclonal antibody and B3/25 monoclonal antibody (17, 18, 23) , which neither inhibits transferrin binding nor cell growth in vitro, shows that each antibody partially interferes with the binding ofthe other, suggesting that the antigenic sites recognized by the two antibodies are juxtaposed although not identical. Thus, a significant factor in the difference between the two antibodies in their ability to block transferrin binding may be that B3/25 monoclonal antibody is an IgG, whereas 42/ 6 monoclonal antibody is a sterically more bulky IgA.
There is considerable evidence suggesting that the primary role of transferrin as a growth factor in vitro is to provide iron (23, (38) (39) (40) (41) (42) . Monoclonal antibodies against T-cell differentiation antigens also have been used in attempts to eliminate tumor cells by immunological effector mechanisms (43) (44) (45) (46) (1982) 
